Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26328605 | 0.96 | CYP2D6 (0.34) | CYP2D6HRH3 | |
| SCHEMBL22918414 | 0.96 | CYP2D6 (0.34) | CYP2D6HRH3 | |
| SCHEMBL22645245 | 0.92 | CYP2D6 (0.36) | CYP2D6HRH3 | |
| SCHEMBL20375693 | 0.90 | CYP2D6 (0.33) | CYP2D6HRH3 | |
| SCHEMBL24735238 | 0.90 | CYP2D6 (0.30) | CYP2D6 | |
| SCHEMBL22645192 | 0.85 | HRH3 (0.30) | HRH3 | |
| SCHEMBL23551954 | 0.85 | HRH3 (0.33) | HRH3 | |
| SCHEMBL10111448 | 0.84 | CYP2D6 (0.42) | CYP2D6HRH3 | |
| SCHEMBL10111441 | 0.82 | CYP2D6 (0.39) | CYP2D6HRH3 | |
| SCHEMBL24941850 | 0.82 | CYP2D6 (0.35) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | CYP2D6 1415/4885HRH3 1453/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | CYP2D6 1415/4885HRH3 1453/4885 |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | CYP2D6 4700/4885HRH3 3021/4885 |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | CYP2D6 4700/4885HRH3 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.